Last edition
News about "Insmed ARIKAYCE"
US FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE
US FDA has granted Priority Review (PR) to Insmed’s ARIKAYCE sNDA for MAC Lung Disease; PDUFA Action Date Set for January 28, 2027.
Insmed ARIKAYCE | 22/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members